| Nov 20 |
Celularity’s Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific
|
| Nov 18 |
Celularity announces resolution of Nasdaq listing compliance matter
|
| Nov 18 |
Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter
|
| Nov 7 |
Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million
|
| Oct 23 |
Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel
|
| Oct 22 |
Celularity Provides Corporate Update
|
| Oct 21 |
Celularity receives Nasdaq notice, intends to file appeal
|
| Oct 18 |
Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal
|
| Oct 16 |
Celularity acquires Rebound product from Sequence Lifescience
|
| Oct 16 |
Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.
|
